Innovative Research Award
Ching-Fei Li — The University of Texas MD Anderson Cancer Center, United States
Ching-Fei Li is a researcher affiliated with The University of Texas MD Anderson Cancer Center whose documented research activity includes molecular mechanisms of cancer progression, tumor biology, and therapeutic strategies. Publicly available research records associate Li with studies involving pancreatic cancer, cancer immunotherapy, lymphoma, and molecular regulation relevant to therapeutic response. [1] [2]
Abstract
Ching-Fei Li’s research profile is centered on cancer biology and therapeutic investigation. Available scholarly records document contributions to research concerning tumor progression, immune regulation, therapeutic resistance, and molecular targets for cancer treatment. The record includes work on pancreatic cancer and cancer immunotherapy, including research examining ADAR1 regulation and the interaction of therapeutic mechanisms with antitumor immune responses. [1] [3]
Keywords
Cancer therapy, cancer biology, cancer immunotherapy, pancreatic cancer, tumor microenvironment, therapeutic resistance, molecular oncology, ADAR1, immune regulation, lymphoma, translational cancer research.
Introduction
Cancer therapy research encompasses the identification of molecular mechanisms that regulate tumor growth, immune evasion, therapeutic response, and disease progression. Within this field, molecular oncology studies seek to connect mechanistic discoveries with potential therapeutic strategies. Public research records identify Ching-Fei Li with work in this broad area at The University of Texas MD Anderson Cancer Center. [2]
Research Profile
The supplied research profile identifies Ching-Fei Li with The University of Texas MD Anderson Cancer Center, United States, and lists cancer therapy as the principal subject area. The supplied bibliometric information records 8 documents, 650 citations, and an h-index of 4. These values should be understood as profile-specific bibliometric data supplied for this recognition page and may change as indexing databases are updated. [4]
Research Contributions
Li’s documented research contributions include studies of molecular pathways relevant to cancer progression and therapeutic intervention. One research direction concerns pancreatic cancer and mechanisms that may influence the response of tumors to immunotherapy. In a 2026 study, Li and collaborators investigated ADAR1 protein regulation and reported that all-trans retinoic acid promotes ADAR1 degradation through a mechanism involving USP7 and retinoylation, with implications for combination treatment involving immune checkpoint blockade. [3]
Publications
The supplied profile information records 8 documents associated with Scopus Author ID 57221912256. The input data identifies the researcher’s subject area as Cancer therapy and provides bibliometric information including 650 citations and an h-index of 4; however, specific publication titles, journals, publication years, complete author lists, and DOI identifiers were not supplied as profile fields. Accordingly, individual publications are not reproduced here to avoid attributing unsupported bibliographic details to the researcher. [4]
Research Impact
The available bibliometric information supplied for this page records 650 citations across 8 documents and an h-index of 4. These figures provide one quantitative description of the research record but should be interpreted in the context of database coverage, publication date, field-specific citation practices, and the changing nature of citation counts. [3]
Award Suitability
For an Innovative Research Award assessment, the documented profile provides several research dimensions that can be considered: cancer therapy, molecular oncology, cancer immunotherapy, pancreatic cancer biology, therapeutic resistance, and investigation of molecular mechanisms relevant to treatment. These areas are represented in the published research record and can be evaluated against the specific eligibility and assessment criteria established by the World Skincare Innovation Awards. [3]
Conclusion
Ching-Fei Li’s documented scholarly profile is associated with cancer therapy and molecular oncology at The University of Texas MD Anderson Cancer Center. The available record includes research concerning cancer immunotherapy, tumor biology, pancreatic cancer, immune regulation, and molecular mechanisms that may influence therapeutic response. [2] [3]
External Links
References
- Elsevier. (n.d.). Scopus author details: Ching-Fei Li, Author ID 57221912256. Scopus.
https://www.scopus.com/authid/detail.uri?authorId=57221912256
- Li, C.-F. et al. (2026). All-trans retinoic acid destabilizes ADAR1 protein through retinoylation-mediated USP7 dissociation and improves immunotherapy in pancreatic cancer. Nature Communications, 17, 6297.DOI:
https://doi.org/10.1038/s41467-026-72271-5
- ORCID. Ching-Fei Li — ORCID record 0000-0001-7844-7003.
https://orcid.org/0000-0001-7844-7003
- Fu, J. et al. (2024). Nardilysin-regulated scission mechanism activates polo-like kinase 3 to suppress the development of pancreatic cancer. Nature Communications.
https://doi.org/10.1038/s41467-024-47242-3